대웅

003090KOSPI의약품 제조업

54.0 / 100

Reference Date: 2026-06-10

Financial Score27.5 / 40

News Sentiment12.5 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but the high debt ratio poses financial risk. Plunged 23.9% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Dae Woong Co., Ltd., a global healthcare group holding company, reported consolidated sales of 2.684 trillion KRW in 2025, a 6.8% increase from the previous year, though operating profit declined 7.1% to 2.618 billion KRW. Its subsidiary Dae Woong Pharm achieved 13.91 trillion KRW in sales and 2.036 billion KRW in operating profit in 2025, driven by growth in key products like Nabohta and Pexuclo, as well as investments in R&D and digital healthcare initiatives.

Number of Employees

413people

Average Salary

69.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

4.26Industry Average 11.938.0Point

Half of industry avg (excellent)

PBR

0.55Industry Average 0.895.5Point

Lower than industry avg (good)

ROE

13.94Industry Average 4.017.0Point

3.5x industry avg (excellent)

Debt Ratio

39.33Industry Average 12.430.0Point

3.2x industry avg (risky)

Trend 2023~20257.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲6.8% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲18.5% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 10.9% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 16,700Won52-week high 29,35052-week low 16,700

1-month return0.0Point

1m -23.92% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0

Neutral기업지배구조보고서공시2026-06-01
Neutral투자판단관련주요경영사항(자회사의 주요경영사항) (엔블로정(Envlo) 0.3mg 멕시코 품목허가 승인)2026-05-26
Neutral투자판단관련주요경영사항(자회사의 주요경영사항) (엔블로젬(Envlozem)의 국내 품목허가 신청)2026-05-26
Neutral투자판단관련주요경영사항(자회사의 주요경영사항) (비만치료용 세마글루타이드(4주 장기지속형 주사제) 기술도입 계약 체결)2026-05-21
Neutral[기재정정]투자판단관련주요경영사항(자회사의 주요경영사항) (mRNA 기반 Epigenetic Reprogramming of Aging (ERA) 기술이전 계약 지위 승계)2026-05-20